Table 1.
Patient characteristics
| Patient characteristics | Total n=93 | Women n=68 | Men n=25 |
| Age median, (IQR) | 60 (52–66) | 60 (51–67) | 60 (52–66) |
| Height (m), mean (SD) | 1.69 (0.90) | 1.66 (0.63) | 1.80 (0.71) |
| Weight (kg), mean (SD) | 76.4 (12.3) | 72.7 (10.9) | 86.8 (9.7) |
| Body mass index (kg/m2), mean (SD) | 26.7 (3.9) | 26.6 (4.1) | 26.9 (3.4) |
| Comorbidity, n (%) | 38 (41) | 30 (44) | 8 (32) |
| Cardiovascular (HT, angina, MI) | 21 (23) | 17 (25) | 4 (16) |
| Respiratory (COPD and/or CRPD) | 18 (19) | 15 (22) | 3 (12) |
| Diabetes | 4 (4) | 3 (4) | 1 (4) |
| Cancer (previous or present) | 5 (5) | 3 (4) | 2 (8) |
| Smoking, n (%)* | |||
| Never smoked | 35 (38) | 27 (40) | 8 (32) |
| Previous smoker | 51 (55) | 37 (54) | 14 (56) |
| Present smoker | 7 (8) | 4 (6) | 3 (12) |
| Resting heart rate (beats per min), mean (SD) | 66 (10) | 67 (9) | 65 (11) |
| Physical activity categories, n (%) | |||
| Does not fulfil ACSM/AHA recommendations | 64 (69) | 44 (66) | 19 (76) |
| Fulfils ACSM/AHA recommendations | 29 (31) | 23 (34) | 6 (24) |
| Seropositivity (ACPA and/or RF), n (%) | 75 (81) | 54 (79) | 21 (84) |
| Disease duration (years), median (IQR) | 10 (5–19) | 10 (5–20) | 11 (6–16) |
| Patient global assessment (0–100 mm), median (IQR) | 24 (10–36) | 27 (16–42) | 12 (5–24) |
| Physician global assessment (0–100 mm), median (IQR) | 10 (0–12) | 8 (0–18) | 5 (0–10) |
| mHAQ, mean (SD) | 0.26 (0.31) | 0.29 (0.33) | 0.17 (0.23) |
| hsCRP, median (IQR) | 1.75 (0.75–3.13) | 1.64 (0.71–3.13) | 2.39 (0.98–3.20) |
| SDAI, n (%) | |||
| Remission | 22 (24) | 12 (18) | 10 (40) |
| Low disease activity | 41 (44) | 32 (47) | 9 (36) |
| Moderate disease activity | 24 (25) | 21 (31) | 3 (12) |
| High disease activity | 6 (7) | 3 (4) | 3 (12) |
| Mean (SD) | 10.2 (8.7) | 10.6 (8.0) | 9.3 (10.3) |
| DAS28 (hsCRP), n (%) | |||
| Remission | 39 (42) | 25 (37) | 14 (56) |
| Low disease activity | 23 (25) | 18 (27) | 5 (20) |
| Moderate disease activity | 28 (30) | 23 (34) | 5 (20) |
| High disease activity | 3 (3) | 2 (3) | 1 (4) |
| Mean (SD) | 2.56 (1.04) | 2.67 (1.01) | 2.27 (1.07) |
| ACR/EULAR remission, n (%) | 25 (27) | 13 (19) | 12 (48) |
| Medication, n (%) | |||
| bDMARDs (present) | 54 (58) | 41 (60) | 13 (52) |
| cDMARDs (present) | 74 (80) | 54 (79) | 20 (80) |
| Corticosteroids (any form during last year) | 39 (42) | 29 (43) | 10 (40) |
*Total sum is 101% due to rounding.
ACPA, anti-citrullinated protein antibody;ACR, American College of Rheumatology;ACSM, American College of Sports Medicine;AHA, American Heart Association;bDMARDs, biological disease-modifying anti-rheumatic drugs;cDMARDs, conventional disease-modifying anti-rheumatic drugs;COPD, chronic obstructive pulmonary disease;CRPD, chronic restrictive pulmonary disease;DAS28, disease activity score index;EULAR, European League Against Rheumatism;hsCRP, high-sensitivity C reactive protein;HT, hypertension;mHAQ, modified Health Assessment Questionnaire;MI, myocardial infarction;PA index, physical activity summary index;RF, rheumatoid factor;SDAI, Simple Disease Activity Index.